APA (7th ed.) Citation

LM, S., MS, R., AA, R., O, d. B., G, B., M, S., . . . E, F. (2026). Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial. American heart journal, 297, 107432. https://doi.org/10.1016/j.ahj.2026.107432

Chicago Style (17th ed.) Citation

LM, Sørensen, et al. "Design and Rationale of the EMPagliflozin After Aortic Valve Replacement (EMPAVR) Study: A Randomized Clinical Trial." American Heart Journal 297 (2026): 107432. https://doi.org/10.1016/j.ahj.2026.107432.

MLA (9th ed.) Citation

LM, Sørensen, et al. "Design and Rationale of the EMPagliflozin After Aortic Valve Replacement (EMPAVR) Study: A Randomized Clinical Trial." American Heart Journal, vol. 297, 2026, p. 107432, https://doi.org/10.1016/j.ahj.2026.107432.